Impact of Morbid Obesity on Left Ventricular Assist Device Support and Heart Transplantation by Cohen, Sophia & Tang, Daniel, MD
Virginia Commonwealth University
VCU Scholars Compass
MD Student Summer Research Fellowship Program
Posters School of Medicine
2016
Impact of Morbid Obesity on Left Ventricular
Assist Device Support and Heart Transplantation
Sophia Cohen
Virginia Commonwealth University, cohense2@vcu.edu
Daniel Tang MD
Virginia Commonwealth University, daniel.tang@vcuhealth.org
Follow this and additional works at: http://scholarscompass.vcu.edu/mds_posters
Part of the Medicine and Health Sciences Commons
This Poster is brought to you for free and open access by the School of Medicine at VCU Scholars Compass. It has been accepted for inclusion in MD
Student Summer Research Fellowship Program Posters by an authorized administrator of VCU Scholars Compass. For more information, please
contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/mds_posters/6
Introduction
Methods
Results Results
References
The current standard of treatment for 
patients with end stage heart failure is 
cardiac transplantation, however, the pool 
of viable donor hearts is not adequate to 
meet the needs of patients with end stage 
heart failure1. This discrepancy has lead to 
the increasing use of continuous flow (CF) 
left ventricular assist devices (LVADs) as a 
bridge to transplant (BTT)2. Patient 
selection is an important predictor of 
outcomes for both LVAD support and Heart 
Transplantation. Morbid obesity, which is a 
BMI ≥ 40, or a BMI ≥ 35 with 
comorbidities3, carries increased risk for 
LVAD placement4 and is a relative 
contraindication for heart transplantation5. 
A higher BMI puts patients at increased 
risk for postoperative complications6. To 
better understand how to best treat heart 
failure in the morbidly obese, we analyzed 
data from patients receiving a CF LVAD 
and heart transplantation to asses the 
association between BMI, complications, 
wait time for transplantation and survival. 
The study was comprised of 157 patients 
with advanced heart failure who received a 
CF LVAD  at Virginia Commonwealth 
University Hospital from December 2008 
through January 2014. We retrospectively 
collected data on each patient from the 
Society of Thoracic Surgeons (STS) and 
Interagency Registry for Mechanically 
Assisted Circulatory Support 
(INTERMACS) databases. The data was 
analyzed by dividing patients into two 
groups, BMI ≥ 35 and BMI < 35.
Morbidly obese patients requiring LVAD 
support encounter higher postoperative 
complications and wait longer for heart 
transplantation, however heart transplant 
and graft survival is comparable. 
Our study suggests that carefully selected 
morbidly obese patients should undergo 
LVAD placement and heart transplantation.  
However, our study was limited by a very 
small sample size and by the biases 
inherent to a retrospective data analysis. 
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Patient Survival After Heart Tx
BMI < 35 BMI ≥ 35
p = 0.7378 by Log-Rank Test
BMI ≥ 35 kg/m2
n=36 (23%)
BMI <35 
kg/m2
n=121 (77%)
P-value
Age in years 47 ± 12.7 55 ± 13.4 0.001
BMI 41.6 ± 5.5 27.8 ± 4.1
Preoperative Comorbidities
Cerebrovascular  Disease 5.6% 17% 0.11
Diabetes 44% 47% 0.85
Prior MI 22% 46% 0.01
Cardiac Arrhythmia 36% 63% 0.01
Implantation Designation
Bridge to Transplant 61% 61%
Bridge to Recovery 3% 7%
Destination 36% 31%
Hemodynamics (mmHg)
Right atrial pressure 18.3 ± 8.8 13.3 ± 5.7 0.004
PCWP 32.4 ± 9.0 27.8 ± 8.0 0.01
Mean PAP 44.7 ± 7.9 38.7 ± 9.6 0.001
Table I. Pre-operative Patient Characteristics 
BMI, body mass index; LVAD, left ventricular assist device; PCWP, 
pulmonary capillary wedge pressure; PAP, Pulmonary artery pressure
BMI ≥ 35 
kg/m2
n=36
BMI <35 
kg/m2
n=121
P-value
Bleeding 
requiring 
reoperation
42% 22% 0.03
Operative 
mortality 
19.5% 11% 0.25
Device Related 
Complications
65% 62% 0.84
Driveline
Infection
Frequency
2.4 ± 1.7 1.2 ± 0.5 0.02
Driveline 
Infection 24% 26% 1
Device 
Thrombosis
26.5% 12% 0.056
Hemolysis 26% 11% 0.05
Stroke 24% 12% 0.10
GI Bleed 20% 26.5% 0.51
Wait time to 
transplant 
(days)
619 ± 372 404 ±
342
0.10
Table II. Post-operative Outcomes and 
Device Related Complications
BMI ≥ 35 kg/m2
n=7
BMI <35 kg/m2
n=41 
P-value
Heart Transplant received in 19% 33% 0.15
Bleeding requiring reoperation 57% 15% 0.03
Length of Hospital Stay (days) 45 ± 43 27 ± 21 0.42
HTx survival at 2.3 ± 1.6 yrs follow up 86% 93% 0.49
Table III. Heart Transplantation 
• 157 LVADs implanted, 121 (77%) BMI <35 and 36 (23%) BMI ≥ 35.
• BMI ≥ 35 group was of 7 years younger, had higher hemodynamics and had fewer prior 
myocardial infarctions, arrythmias, and cardiac surgeries. 
• Both groups had comparable preop morbidities, INTERMACS class, LVAD type and 
implantation designation. 
• Postop and device specific complications were higher in BMI ≥35 group, but only bleeding 
requiring reoperation and frequency of driveline infections were statistically significant. 
• Operative mortality higher in BMI ≥35 group but wasn’t statistically significant (19.5% vs 11%).
• Patients with a BMI ≥ 35 spent an average of 216 more days on the wait list, with an average of 
(619 ± 372 vs 403 ± 342 days) and fewer patients received a HTx (19% vs. 33% p = 0.15) 
• After HTx, BMI ≥35 group had higher postop bleeding requiring reoperation (57% vs 15%).
• HTx survival and graft survival was comparable in both groups.  Discussion
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